Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Payables: 2023-2025

Historic Payables for Compass Therapeutics (CMPX) over the last 3 years, with Sep 2025 value amounting to $3.1 million.

  • Compass Therapeutics' Payables rose 222.40% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.5 million, marking a year-over-year increase of 34.10%. This contributed to the annual value of $2.2 million for FY2024, which is 45.01% down from last year.
  • Latest data reveals that Compass Therapeutics reported Payables of $3.1 million as of Q3 2025, which was up 19.27% from $2.6 million recorded in Q2 2025.
  • Compass Therapeutics' 5-year Payables high stood at $4.1 million for Q4 2023, and its period low was $724,000 during Q2 2023.
  • Over the past 3 years, Compass Therapeutics' median Payables value was $1.6 million (recorded in 2025), while the average stood at $1.9 million.
  • Its Payables has fluctuated over the past 5 years, first slumped by 58.37% in 2024, then surged by 222.40% in 2025.
  • Compass Therapeutics' Payables (Quarterly) stood at $4.1 million in 2023, then plummeted by 45.01% to $2.2 million in 2024, then spiked by 222.40% to $3.1 million in 2025.
  • Its Payables stands at $3.1 million for Q3 2025, versus $2.6 million for Q2 2025 and $1.6 million for Q1 2025.